Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DR0B6F
|
|||
| Drug Name |
Donidalorsen
|
|||
| Drug Type |
Ligand-conjugated antisense
|
|||
| Indication | Hereditary angioedema [ICD-11: 4A00.14; ICD-9: 277.6] | Phase 3 | [1] | |
| Company |
Ionis
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Plasma kallikrein messenger RNA (KLKB1 mRNA) | Target Info | . | [2] |
| KEGG Pathway | Complement and coagulation cascades | |||
| NetPath Pathway | AndrogenReceptor Signaling Pathway | |||
| Panther Pathway | Blood coagulation | |||
| Pathwhiz Pathway | Coagulation | |||
| Reactome | Intrinsic Pathway of Fibrin Clot Formation | |||
| Activation of Matrix Metalloproteinases | ||||
| WikiPathways | Complement and Coagulation Cascades | |||
| Human Complement System | ||||
| Blood Clotting Cascade | ||||
| Formation of Fibrin Clot (Clotting Cascade) | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05392114) An Open-Label, Long Term Safety and Efficacy Study of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE). U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Ionis | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.